Literature DB >> 11739554

MIP-1alpha regulates CD4+ T cell chemotaxis and indirectly enhances PMN persistence in Pseudomonas aeruginosa corneal infection.

K A Kernacki1, R P Barrett, S McClellan, L D Hazlett.   

Abstract

The role of macrophage inflammatory protein-1alpha (MIP-1alpha) in cell infiltration into Pseudomonas aeruginosa-infected cornea and subsequent disease was examined. Greater amounts of the chemokine (protein and mRNA) were found in the infected cornea of susceptible B6 ("cornea perforates") versus resistant BALB/c ("cornea heals") mice from 1 to 5 days postinfection. Treatment of BALB/c mice with recombinant (r) MIP-1alpha exacerbated disease and was associated with an increased number of neutrophils (PMNs) in the cornea. Treatment of BALB/c mice with rMIP-1alpha also induced recruitment of activated CD4+ T cells into the affected cornea, converting resistant to susceptible mice. Depleting CD4+ T cells in r-treated BALB/c mice significantly decreased PMNs in cornea tissue, suggesting that T cells regulate persistence of PMNs at this site. In B6 mice, administration of neutralizing MIP-1alpha polyclonal antibody also significantly reduced PMN numbers and pathology. Collectively, evidence is provided that MIP-1alpha directly contributed to CD4+ T cell recruitment and indirectly to PMN persistence in the infected cornea.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739554

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  8 in total

1.  TREM-1 amplifies corneal inflammation after Pseudomonas aeruginosa infection by modulating Toll-like receptor signaling and Th1/Th2-type immune responses.

Authors:  Minhao Wu; Anping Peng; Mingxia Sun; Qiuchan Deng; Linda D Hazlett; Jin Yuan; Xialin Liu; Qianying Gao; Lianqiang Feng; Junfang He; Ping Zhang; Xi Huang
Journal:  Infect Immun       Date:  2011-05-09       Impact factor: 3.441

2.  TREM-2 promotes host resistance against Pseudomonas aeruginosa infection by suppressing corneal inflammation via a PI3K/Akt signaling pathway.

Authors:  Mingxia Sun; Min Zhu; Kang Chen; Xinxin Nie; Qiuchan Deng; Linda D Hazlett; Yongjian Wu; Meiyu Li; Minhao Wu; Xi Huang
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-05-17       Impact factor: 4.799

3.  Expression and potential role of major inflammatory cytokines in experimental keratomycosis.

Authors:  Wenxian Zhong; Hongmei Yin; Lixin Xie
Journal:  Mol Vis       Date:  2009-07-04       Impact factor: 2.367

4.  An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites.

Authors:  Xinping Fu; Armando Rivera; Lihua Tao; Xiaoliu Zhang
Journal:  Oncotarget       Date:  2015-01-20

5.  Prophylactic Knockdown of the miR-183/96/182 Cluster Ameliorates Pseudomonas aeruginosa-Induced Keratitis.

Authors:  Sharon McClellan; Ahalya Pitchaikannu; Robert Wright; Denise Bessert; Mason Iulianelli; Linda D Hazlett; Shunbin Xu
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-12-01       Impact factor: 4.925

Review 6.  Foundational concepts in the biology of bacterial keratitis.

Authors:  Lawson Ung; James Chodosh
Journal:  Exp Eye Res       Date:  2021-06-05       Impact factor: 3.770

7.  Inactivation of the miR-183/96/182 Cluster Decreases the Severity of Pseudomonas aeruginosa-Induced Keratitis.

Authors:  Chithra K Muraleedharan; Sharon A McClellan; Ronald P Barrett; Cui Li; Daniel Montenegro; Thomas Carion; Elizabeth Berger; Linda D Hazlett; Shunbin Xu
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-04       Impact factor: 4.799

8.  Persistence of Innate Immune Pathways in Late Stage Human Bacterial and Fungal Keratitis: Results from a Comparative Transcriptome Analysis.

Authors:  Jaya D Chidambaram; Shichina Kannambath; Palepu Srikanthi; Manisha Shah; Prajna Lalitha; Shanmugam Elakkiya; Julien Bauer; Namperumalsamy V Prajna; Martin J Holland; Matthew J Burton
Journal:  Front Cell Infect Microbiol       Date:  2017-05-18       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.